Financials in USD. Standardized financial statements.
A compact view of how Polydex Pharmaceuticals Limited turns revenue into operating income and net income.
| Metric | FY 2009 | FY 2008 | FY 2007 | FY 2006 | FY 2005 | FY 2004 | FY 2003 | FY 2002 | FY 2001 | FY 2000 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $4.48M | $4.82M | $5.73M | $6.50M | $5.27M | $6.37M | $14.09M | $12.79M | $12.17M | $13.65M |
| Revenue Growth? | -7.1% | -15.9% | -11.8% | +23.4% | -17.4% | -54.8% | +10.2% | +5.1% | -10.8% | 0.0% |
| Cost of Revenue? | $4.57M | $4.79M | $5.36M | $5.67M | $4.84M | $4.39M | $10.74M | $9.53M | $9.43M | $10.00M |
| Gross Profit? | -$91,725 | $31,903 | $375,064 | $832,443 | $429,185 | $1.98M | $3.35M | $3.26M | $2.74M | $3.65M |
| Gross Margin? | -2.0% | +0.7% | +6.5% | +12.8% | +8.2% | +31.1% | +23.8% | +25.5% | +22.5% | +26.7% |
| Operating Expenses? | $1.10M | $1.14M | $1.39M | $1.63M | $1.82M | $2.19M | $2.77M | $2.81M | $2.81M | $3.59M |
| Operating Income? | -$1.18M | -$2.06M | -$1.01M | -$801,568 | -$1.39M | -$209,953 | $574,752 | $449,736 | -$75,695 | $57,808 |
| EBITDA? | -$745,926 | -$1.51M | -$489,825 | -$276,677 | -$831,041 | -$1.70M | $2.03M | $1.51M | $395,427 | $477,109 |
| Income Before Tax | -$2.14M | -$1.64M | -$967,155 | -$375,818 | -$1.31M | $1.71M | -$395,967 | $77,625 | -$37,898 | $274,887 |
| Income Tax Expense | $54,623 | -$52,960 | -$81,944 | -$115,195 | $180,757 | $566,866 | -$389,968 | $751,366 | $168,982 | $143,603 |
| Net Income? | -$2.20M | -$1.59M | -$885,211 | -$260,623 | -$1.49M | $1.14M | -$5,999 | -$673,741 | -$206,880 | $131,284 |
| EPS? | $-0.72 | $-0.52 | $-0.29 | $-0.09 | $-0.49 | $0.38 | $-0.00 | $-0.22 | $-0.07 | $0.04 |
| Diluted EPS? | $-0.72 | $-0.52 | $-0.29 | $-0.09 | $-0.49 | $0.37 | $-0.00 | $-0.22 | $-0.07 | $0.04 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality